Report copyright - KEYTRUDA® (pembrolizumab) Powdergenomic tumor aberrations. (1.2, 2.1) • as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%)
Please pass captcha verification before submit form